Although ctDNA positivity generally meant worse disease-free survival in stage 3 resected colon cancer, patients with ctDNA ...

Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete ...

A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham ...

Aspirin reduced disease recurrence in patients PI3K-mutated colorectal cancer, underscoring the value of early genomic ...

Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with ...

Adjuvant treatment with aspirin is associated with a lower risk of recurrence at 3 years in CRC patients with PI3K pathway ...

About 150,000 Americans are diagnosed annually with colorectal cancer, which occurs when cells in the colon or rectum grow ...

Safety: Aspirin was well-tolerated, with no major safety concerns reported. The ASCOLT trial showed that aspirin did not ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with ...

Event planner and colorectal cancer survivor Kim Hall-Jackson tells us how she hopes to improve rates of diagnosis, help people through their journeys and make the voices in the patient community ...

A new targeted approach, which combines a drug called encorafenib with cetuximab and chemotherapy regimen mFOLFOX6, has received accelerated FDA approval for metastatic colorectal cancer with a BRAF ...